Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease

European Journal of Health Economics

Volumn 14, Issue 6, 2013, Pages 853-861

  Marchetti, Monia ^a   Liberato, Nicola L ^b   Di Sabatino, Antonio ^c   Corazza, Gino R ^c  

^a CARDINAL MASSAIA HOSPITAL   (Italy)

^b Ospedale C Mira Piazzale Volontari Del Sangue   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Cost effectiveness; Crohn's disease; Infliximab; Step up; Top down

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; METHYLPREDNISOLONE;

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CROHN DISEASE; DRUG COST; HEALTH CARE COST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE SURGERY; LIFE EXPECTANCY; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS;

ANTIBODIES, MONOCLONAL; AZATHIOPRINE; COST-BENEFIT ANALYSIS; CROHN DISEASE; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS;

EID: 84888437846     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-012-0430-7     Document Type: Article

References (35)

1. Targan, S.R.; Hanauer, S.B.; van Deventer, S.J.; Mayer, L.; Present, D.H.; Braakman, T.; DeWoody, K.L.; Schaible, T.F.; Rutgeerts, P.J.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 study group. N. Engl. J. Med. 337, 1029-1035 (1997)
2. Present, D.H.; Rutgeerts, P.; Targan, S.; Hanauer, S.B.; Mayer, L.; van Hogezand, R.A.; Podolsky, D.K.; Sands, B.E.; Braakman, T.; DeWoody, K.L.; Schaible, T.F.; van Deventer, S.J.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340, 1398-1405 (1999)
3. Sandborn, W.J.; Feagan, B.G.; Hanauer, S.B.; Present, D.H.; Sutherland, L.R.; Kamm, M.A.; Wolf, D.C.; Baker, J.P.; Hawkey, C.; Archambault, A.; Bernstein, C.N.; Novak, C.; Heath, P.K.; Targan, S.R.: CDP571 Crohn's disease study group: an engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120, 1330-1338 (2001)
4. Dignass, A.; Van Assche, G.; Lindsay, J.O.; Lemann, M.; Soderholm, J.; Colombel, J.F.; Danese, S.; D'Hoore, A.; Gassull, M.; Gomollon, F.; Hommes, D.W.; Michetti, P.; O'Morain, C.; Oresland, T.; Windsor, A.; Stange, E.F.; Travis, S.P.: European Crohn's and Colitis Organisation (ECCO): the second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J. Crohn's Colitis 4, 28-62 (2010)
5. Lichtenstein, G.R.; Abreu, M.T.; Cohen, R.; Tremaine, W.: American gastroenterological association: American gastroenterological association institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130, 935-939 (2006)
6. D'Haens, G.R.; Panaccione, R.; Higgins, P.D.; Vermeire, S.; Gassull, M.; Chowers, Y.; Hanauer, S.B.; Herfarth, H.; Hommes, D.W.; Kamm, M.; Lofberg, R.; Quary, A.; Sands, B.; Sood, A.; Watermeyer, G.; Lashner, B.; Lemann, M.; Plevy, S.; Reinisch, W.; Schreiber, S.; Siegel, C.; Targan, S.; Watanabe, M.; Feagan, B.; Sandborn, W.J.; Colombel, J.F.; Travis, S.: The London position statement of the world congress of gastroenterology on biological therapy for IBD with European Crohn's and colitis organization: when to start, when to stop, which drug to choose, and how to predict response? Am. J. Gastroenterol. 106, 199-212 (2011)
7. van Assche, G.; Vermeire, S.; Rutgeerts, P.: Mucosal healing and anti TNFs in IBD. Curr. Drug Targets 11, 227-233 (2010)
8. van Assche, G.; Vermeire, S.; Rutgeerts, P.: The potential for disease modification in Crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 7, 79-85 (2010)
9. Lémann, M.; Mary, J.Y.; Duclos, B.; Veyrac, M.; Dupas, J.L.; Delchier, J.C.; Laharie, D.; Moreau, J.; Cadiot, G.; Picon, L.; Bourreille, A.; Sobahni, I.; Colombel, J.F.: Group d'Etude therapeutique del affections inflammatoires du tube digestif (GETAID): infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 130, 1054-1061 (2006)
10. D'Haens, G.; Baert, F.; van Assche, G.; Caenepeel, P.; Vergauwe, P.; Tuynman, H.; De Vos, M.; van Deventer, S.; Stitt, L.; Donner, A.; Vermeire, S.; Van de Mierop, F.J.; Coche, J.C.; van der Woude, J.; Ochsenkuhn, T.; van Bodegraven, A.A.; Van Hootegem, P.P.; Lambrecht, G.L.; Mana, F.; Rutgeerts, P.; Feagan, B.G.; Hommes, D.: Belgian inflammatory bowel diseae research group; North-Holland gut club: early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371, 660-667 (2008)
11. Baert, F.J.; Moortgat, L.; Van Assche, G.A.; Caenepeel, P.; Vergauwe, P.L.; De Vos, M.; Stokkers, P.C.; Hommes, D.W.; Vermeire, S.; Ritgeerts, P.J.; Feagan, B.G.; D'Haens, G.: Mucosal healing predicts sustained clinical remission in early Crohn's disease. Gastroenterology 134(suppl. 1), A640 (2008)
12. Silverstein, M.D.; Loftus, E.V.; Sandborn, W.J.; Tremaine, W.J.; Feagan, B.G.; Nietert, P.J.; Harmsen, W.S.; Zinsmeister, A.R.: Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 117, 49-57 (1999)
13. Faraawi, R.; Khraishi, M.; Choquette, D.; Bensen W.; Nantel F.: The remitrac infusion registry: safety and management of infliximab infusions in a real-life setting. Gastroenterology 134 (Suppl 1), A-662 (2008)
14. Buxton, M.J.; Lacey, L.A.; Feagan, B.G.; Niecko, T.; Miller, D.W.; Townend, R.J.: Mapping from disease-specific measures to utility: an analysis of the relationship between the inflammatory bowel disease questionnaire and Crohn's disease activity index in Crohn's disease and measures of utility. Value Health 10, 214-220 (2007)
15. Casellas, F.; Arenas, J.; Badet, J.: Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm. Bowel Dis. 11, 488-496 (2005)
16. Marchal, L.; D'Haens, G.; Van Assche, G.; Vermeire, S.; Noman, M.; Ferrante, M.; Hiele, M.; Bueno De Mesquita, M.; D'Hoore, A.; Penninckx, F.; Rutgeerts, P.: The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment. Pharmacol. Ther. 19, 749-754 (2004)
17. Jewell, D.P.; Satsangi, J.; Lobo, A.; Probert, C.; Forbes, A.; Ghosh, S.; Shaffer, J.; Frenz, M.; Drummond, H.; Troy, G.; Turner, S.; Younge, L.; Evans, L.; Moosa, M.; Rodgers-Gray, B.; Buchan, S.: Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur. J. Gastroenterol. Hepatol. 17, 1047-1052 (2005)
18. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal (June 2008). Available at: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed 8 Apr 2012
19. Hanauer, S.B.; Feagan, B.G.; Lichtenstein, G.R.; Mayer, L.F.; Schreiber, S.; Colombel, J.F.; Rachmilewitz, D.; Wolf, D.C.; Olson, A.; Bao, W.; Rutgeerts, P.: ACCENT I study group: maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541-1549 (2002)
20. Marshall, J.; Blackhouse, G.; Goeree, R.; Brazier N.; Irvine E.; Faulkner L.; Dipchand C.; O'Brien B.: Infliximab for the treatment of Crohn's disease: a systematic review and cost-utility analysis. Canadian Coordinating Office for Health Technology Assessment, Ottawa (2002). Technology report no 24. Available at: http://cadth.ca/media/pdf/122-infliximab-tr-e.pdf. Accessed 8 Apr 2012
21. Jaisson-Hot, I.; Flouriè, B.; Descos, L.; Colin, C.: Management for severe Crohn's disease: a lifetime cost-utility analysis. Int. J. Technol. Assess. Health Care 20, 274-279 (2004)
22. Lindsay, J.; Punekar, Y.S.; Morris, J.; Chung-Faye, G.: Health economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease - modelling outcomes in active luminal and fistulising disease in adults. Aliment. Pharmacol. Ther. 28, 76-87 (2008)
23. Bodger, K.; Kikuchi, T.; Hughes, D.: Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment. Pharmacol. Ther. 30, 265-274 (2009)
24. Bernstein, C.N.; Nabalamba, A.: Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am. J. Gastroenterol. 101, 110-118 (2006)
25. Yu, A.P.; Cabanilla, L.A.; Wu, E.Q.; Mulani, P.M.; Chao, J.: The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr. Med. Res. Opin. 24, 319-328 (2008)
26. Rubenstein, J.H.; Chong, R.Y.; Cohen, R.D.: Infliximab decreases resource use among patients with Crohn's disease. J. Clin. Gastroenterol. 35, 151-156 (2002)
27. Sprakes, M.B.; Ford, A.C.; Suares, N.C.; Warren, L.; Greer, D.; Donnellan, C.F.; Jennings, J.S.; Everett, S.M.; Hamlin, P.J.: Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience. Aliment. Pharmacol. Ther. 32, 1357-1363 (2010)
28. Saro, C.; da la Coba, C.; Casado, M.A.; Morales, J.M.; Otero, B.: Resource use in patients with Crohn's disease treated with infliximab. Aliment. Pharmacol. Ther. 26, 1313-1323 (2007)
29. Yu, A.P.; Johnson, S.; Wang, S.T.; Atanasov, P.; Tang, J.; Wu, E.; Chao, J.; Mulani, P.M.: Cost-utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease. Pharmacoeconomics 27, 609-621 (2009)
30. Xie F.; Blackhouse G.; Assasi N.; Gaebel K.; Robertson D.; Goeree R.: Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost. Eff. Resour. Alloc. 7: 20 (2009). Available at: http://www.resource-allocation.com/content/pdf/1478-7547-7-20.pdf. Accessed 8 Apr 2012
31. Gregor, J.C.; McDonald, J.W.D.; Klar, N.; Wall, R.; Atkinson, K.; Lamba, B.; Feagan, B.G.: An evaluation of utility measures in Crohn's disease. Inflamm. Bowel Dis. 3, 265-276 (1997)
32. Juan, J.; Estiarte, R.; Colomé, E.; Artes, M.; Jimenez, F.J.; Alonso, J.: Burden of illness of Crohn's disease in Spain. Dig. Liver Dis. 35, 853-861 (2003)
33. Feagan, B.G.; Bala, M.; Yan, S.; Olson, A.; Hanauer, S.: Unemployment and disability in patients with moderately to severely active Crohn's disease. J. Clin. Gastroenterol. 39, 390-395 (2005)
34. Lichtenstein, G.R.; Yan, S.; Bala, M.; Hanauer, S.: Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am. J. Gastroenterol. 99, 91-96 (2004)
35. Colombel, J.F.; Sandborn, W.J.; Reinisch, W.; Mantzaris, G.J.; Kornbluth, A.; Rachmilewitz, D.; Lichtiger, S.; D'Haens, G.; Diamond, R.H.; Broussard, D.L.; Tang, K.L.; van der Woude, C.J.; Rutgeerts, P.: SONIC study group: infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 32, 1383-1395 (2010)